H2AFZ、MLF1IP和NEK2在乳腺癌不同亚型中的表达差异与预后相关性分析

Correlation analysis between expression levels of H2AFZ,MLF1IP and NEK2 in cross-subtype diversity of breast cancer and prognosis

目的:寻找与乳腺癌分型和预后相关的全新分子标志物,为乳腺癌的诊疗提供依据.方法:本研究借助生物信息学手段和统计学方法对多个来自肿瘤公共数据库的大样本数据进行了深度分析.结果:H2AFZ、MLF1IP和NEK2为乳腺癌不利预后因子,三者皆与乳腺癌患者ER/PR/HER2表达水平具有显著的相关性.H2AFZ、MLF1IP和NEK2的mRNA水平在ER和PR阳性乳腺癌中低表达,而在HER2阳性乳腺癌中高表达.此外,H2AFZ、MLF1IP和NEK2在乳腺癌Luminal A亚型中的表达水平较低,而且与预后负相关,而在其他亚型中水平较高,与预后相关性不大.结论:作为不利预后因子,H2AFZ、MLF1IP和NEK2在乳腺癌患者不同分型人群中的表达差异可能是造成乳腺癌各分型恶性程度和预后差异的原因之一.

AIM： To investigate potential biomarkers associated with breast cancer molecular subtyping and prognosis,and provide basis for diagnosis and treatment of breast cancer. METHODS：Large-sample data of breast cancer sets extracted from public online databases were analyzed by bioinformatics and statistics.RESULTS： H2AFZ,MLF1IP and NEK2 were negative prognostic factors of breast cancer,and they were significantly correlated with the expression level of ER/PR/HER2 in breast cancer patients.The mRNA of H2AFZ,MLF1IP,NEK2 showed low levels in ER and PR-positive breast cancer,while were highly expressed in HER2-positive breast cancer. The expression levels of H2AFZ,MLF1IP,NEK2 in Luminal A were lower,and were negatively correlatied with prognosis, meanwhile the expression levels of H2AFZ,MLF1IP,NEK2 in the other subtypes were higher,and the correlation between H2AFZ,MLF1IP,NEK2 and prognosis was not significant. CONCLUSION： As adverse-prognostic factors,the different expression of these molecules might be one of the reasons causing the malignant degree and prognostic differences among breast cancer subtyping.